---
schema_version: "secwatch.filing_event.v1"
accession: "0001645666-25-000009"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:50:19.088126+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M

## Summary
- 31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).
- In steroid-dependent subgroup, 36% zetomipzomib CR + taper ≤5 mg/day vs 0% placebo; median response 27.6 weeks.
- No Grade 4/5 AEs; injection site reactions most common; one placebo SAE (variceal bleed), two zetomipzomib SAEs (fever, flu).
- FY2024 net loss $83.7M vs $101.9M in 2023; cash $132.2M at Dec 31, 2024.
- Company plans to discuss with FDA to remove partial clinical hold and design registrational trial.

## SEC filing metadata
- accession: 0001645666-25-000009
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/0001645666-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/kzr-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645666-25-000009
- JSON: https://secwatch.observer/filing/0001645666-25-000009.json
- Plain text: https://secwatch.observer/filing/0001645666-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.